Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Launches The Desire Project to Promote MDMA-Assisted Psychotherapy Treatment for HSDD

• Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone
• The project gathers some of the world’s leading researchers in female sexual desire and psychedelics
• This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications
• Clinical trials of MDMA as a treatment for PTSD have shown some success due to targeting the pathways that process fear
• MINDCURE is working with a molecule that will be first-to-market – MDMA is predicted to be approved by 2023 – this brings them closer to the money

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a diversified life sciences company currently at the forefront of innovating and improving mental health through the research and use of psychedelic compounds, is pleased to announce the launch of its “Desire Project” to address and treat female Hypoactive Sexual Desire Disorder (“HSDD”) with MDMA-assisted psychotherapy. The Desire Project is the first-of-its-kind study targeting this sexual disorder which affects an estimated 9.5 million premenopausal women in the United States alone. The benefits of the study could potentially impact women and relationships on a worldwide level (https://ibn.fm/uC78c). 

HSDD is a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. According to current estimates, 40% of women in the US have self-reported low sexual desire, with HSDD affecting 10% of adult women and 14% of premenopausal adult women. Men can also suffer from HSDD.

“MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way. We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind,” MINDCURE President and CEO Kelsey Ramsden said. “Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire.”

In clinical trials using MDMA, some success has been shown in post-traumatic stress disorder (“PTSD”) patients. The MDMA treatment works on the brain’s pathways related to fear. It can help enhance fear memory extinction, modulate fear memory reconsolidation, and even bolster the social behavior in animal tests. MINDCURE has spent six months planning the upcoming Desire Project with a strong emphasis on how MDMA may ease some of the fear factors in women, which could play a large role in female-related sexual disorders that are not currently treatable by methods or medications on the market.

The Desire Project comprises some of the world’s leading researchers in female sexual desire and psychedelics. These world-renowned names include:

• Dr. Anita Clayton (Professor and chair of the Department of Psychiatry and Neurobehavior Sciences and a Professor of Clinical Obstetrics and Gynecology at the University of Virginia), Dr. Jennifer Mitchell (lead author of MAPS MDMA-assisted therapy for PTSD study), 
• Dr. Cindy Meston (directs the Female Sexual Psychophysiology Laboratory at the University of Texas in Austin), 
• Dr. Robert Pyke (leader of the Addyl project, a drug used to treat the symptoms of HSDD and has author of over 100 peer-reviewed publications in the last 18 years), and
• Dr. Sherry Walling (a practicing, licensed clinical psychologist with a master’s degree in theology and emphasis on trauma).

“During my decades as a psychiatrist, I’ve seen first-hand the limitations of existing treatments. This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder,” Mind Cure Health CMO Dr. Joel Raskin, MD, said (https://ibn.fm/4MJOp). Living with HSDD can damage the lives of the women it affects, causing depression and anxiety – potentially destroying personal relationships. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from this disorder.

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.